Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Pediatr Infect Dis J. 2013 Sep;32(9):e370–e376. doi: 10.1097/INF.0b013e31828e8c09

Figure 2.

Figure 2

Percentages of nucleoside reverse transcriptase inhibitor only antiretroviral regimen (NOAR)-treated and highly active antiretroviral therapy(HAART)-treated participants with adverse events reported at any time during the treatment period. LEGACY cohort, 2001-2006.

Note: Only P-values < 0.05 are shown. P-values noted above represent comparisons between the NOAR and HAART columns for leukopenia(*) and anemia(†).

P-values for other adverse events are ≥ 0.05.